In a report released today, Gregory Aurand from Noble Financial maintained a Buy rating on Baudax Bio (BXRX – Research Report), with a price target of $0.60. The company’s shares closed yesterday at $0.14.
Aurand covers the Healthcare sector, focusing on stocks such as Baudax Bio, ChitogenX, and BioSig Technologies. According to TipRanks, Aurand has an average return of -60.9% and a 17.65% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Baudax Bio with a $0.60 average price target.
The company has a one-year high of $18.86 and a one-year low of $0.13. Currently, Baudax Bio has an average volume of 1.91M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Baudax Bio, Inc. is a pharmaceutical company focusing on developing and commercializing products for acute care settings. The company was founded in 2015 and is headquartered in Malvern, PA.
Read More on BXRX: